Balance Sheet
Cash Flow Statement
Cash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Change in Cash (2016 - 2025)

Historic Change in Cash for Alaunos Therapeutics (TCRT) over the last 15 years, with Q3 2025 value amounting to -$941000.0.

  • Alaunos Therapeutics' Change in Cash fell 2048.66% to -$941000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $255000.0, marking a year-over-year increase of 10248.51%. This contributed to the annual value of -$5.0 million for FY2024, which is 8940.85% up from last year.
  • Per Alaunos Therapeutics' latest filing, its Change in Cash stood at -$941000.0 for Q3 2025, which was down 2048.66% from $2.6 million recorded in Q2 2025.
  • In the past 5 years, Alaunos Therapeutics' Change in Cash registered a high of $15.0 million during Q3 2021, and its lowest value of -$23.3 million during Q2 2021.
  • Moreover, its 5-year median value for Change in Cash was -$5.9 million (2023), whereas its average is -$6.0 million.
  • Its Change in Cash has fluctuated over the past 5 years, first plummeted by 57018.39% in 2023, then skyrocketed by 25229.03% in 2025.
  • Over the past 5 years, Alaunos Therapeutics' Change in Cash (Quarter) stood at -$15.7 million in 2021, then surged by 107.98% to $1.3 million in 2022, then plummeted by 570.18% to -$5.9 million in 2023, then soared by 89.94% to -$592000.0 in 2024, then crashed by 58.95% to -$941000.0 in 2025.
  • Its Change in Cash stands at -$941000.0 for Q3 2025, versus $2.6 million for Q2 2025 and -$772000.0 for Q1 2025.